POLE Mutation

CI-VAR-00002691Explore in graph →CIViC 797

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma1
POLE Mutation	Pembrolizumab	Predictive	C	Supports Sensitivity Response	3	accepted	EID1861 Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasi… (full text at CIViC) PMID 27683556 · Johanns et al., 2016 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
POLE Mutation	Pembrolizumab	Predictive	C	Supports Sensitivity Response	3	submitted	EID7469 In a case report, patient with metastatic colorectal cancer harboring MSS and POLE mutation was treated with pembrolizumab and showed tumor response. PMID 28188185 · Gong et al., 2017 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Endometrial Neoplasm1
POLE Mutation	Pembrolizumab	Predictive	C	Supports Sensitivity Response	3	accepted	EID1862 Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary… (full text at CIViC) PMID 27159395 · Mehnert et al., 2016 · Open in CIViC	civic